What's coming,and how surewe are

Three drugs are racing for the first-ever approval in advanced liver cirrhosis, and most people still write the whole area off.

Right now this ends in a transplant or death. A first approval creates a standard of care where none exists.

Does Novo Nordisk publish its SYNCHRONY Real-World Phase 3 headline result by 31 Dec 2026 with no new safety problem in the cirrhosis group?

The bet is on the method of switching genes off reversibly, not on the hepatitis drug that happens to be testing it first.

If it holds up in people it opens a whole class of medicines, far beyond this one disease.

Is a second-stage trial of TUNE-401 registered and recruiting patients on or before 30 Jun 2027?

Not “AI helped make a drug”. The test is whether AI proposed a target humans had missed, the only version of the claim that would be new.

It is the difference between AI as a faster tool and AI as a source of new science.

Does Insilico’s mid-2026 report say the rentosertib Phase 3 trial is still running, not paused, stopped or on hold?

The edge is not whether it works. It is that the market will read the coming trial result as a final verdict when it is only a halfway look.

It affects roughly one person in five and there is nothing to offer them today.

Is the Lp(a)HORIZON trial presented in a headline session at the American Heart Association meeting in November 2026?

The mispricing is commercial, not scientific. Everyone assumes antibiotics never make money, so the clinical result gets ignored entirely.

Drug-resistant infection is a slow-moving crisis and the pipeline has been close to empty for decades.

Does Roche present zosurabalpin results from infected patients at IDWeek in October 2026?

Specifically the boring hardware, not generating the power, which is now the story everyone tells.

It puts a hard ceiling on how fast AI capacity can be built, no matter how much money is thrown at it.

On its next earnings call, does Microsoft again say AI capacity is limited by power and buildings rather than chip supply?

Turbines are physically sold out, so solar plus batteries wins the buildout by default. That is a supply fact, not a policy preference.

It decides what the US grid is actually built out of for the rest of this decade.

Does GE Vernova report a gas-turbine order book of 125 GW or more at the end of 2026, with factory capacity still around 20 GW a year?

A live test of whether Chinese state programmes hit the dates they announce. It is the same question the medicine bets ask, pointed the other way.

Satellite internet is strategic infrastructure, and this measures what Chinese announcements are actually worth.

Do total Qianfan satellites launched reach 324, the operator’s own restated target, by the end of 2026? (238 were in orbit in July 2026.)

A pure measurement of capability. The “so US AI gets throttled” half was cut because it repeated the transformer wall.

Electricity is the input to everything downstream: industry, AI, transport. A sustained gap compounds.

Do China’s new generating-capacity additions for 2026 come in at three times the US total or more?

The insight is the reason. The new maths is ready; the map of what needs replacing is not.

Data stolen today can be unlocked later. The migration is the only thing standing in the way.

Does the White House budget office issue the required post-quantum guidance on or before 30 Sep 2026, as the executive order’s 90-day clock demands?

Not whether small reactors work, but whether any meaningful amount is actually generating power for data centres before 2030.

If the nuclear answer lands in the 2030s, the power problem has to be solved some other way first.

After the August 2026 hearing, does the regulator issue the construction permit for TVA’s Clinch River reactor by 31 Dec 2026?

The bet is that China builds them for supply-security reasons even while lithium is cheap, against the cost logic Western analysts rely on.

It would cut grid storage loose from lithium supply, which is a strategic weak point for everyone else.

Does CATL’s Q3-2026 disclosure confirm that commercial sodium-ion grid-battery deliveries actually began in September 2026 as guided?

Betting against a trade that has ruined people for thirty years. The claim is that this time the buyer of last resort is stepping back.

Japanese money is invested all over the world. If it comes home, borrowing costs rise everywhere.

Does Japan’s finance ministry ask for 35 trillion yen or more to service its debt next year? (Last year’s request: 32.4 trillion.)

The only position here that pays when the AI buildout fails: cover for four other bets, not another bet alongside them.

It is the financial fault line under the AI boom, and some of this debt is currently rated as safe.

Does CoreWeave’s Q2-2026 report show interest costs above 28% of quarterly revenue? (Q1-2026: 25.8%.)

Already played out in the price. Kept for scoring and for its checkpoints, not as a live idea.

Fuel costs feed into every reactor running and planned, though most of this is in the price already.

Does Centrus’s Q2-2026 report say the average price it achieved for enrichment rose year on year? (Q1-2026: up 52%.)